glp-1 agonist in esrd and the kidney: from physiology to pharmacology and outcomes diabetes π΄SGLT2 Inhibitors and GLP-1 Receptor
Description
2020;32:e13738
Mol Med Rep (2012) 5(3):72933
Liraglutide has been shown in studies to cause thyroid tumors in animals, but it's not yet known if it can cause thyroid cancer in people
Prevention candidates: Given the observational data suggesting reduced autoimmune disease risk in GLP-1 users, some practitioners are considering microdosing for patients with strong family histories or early biomarker evidence of autoimmune activation before clinical disease manifests
Tissue processing and quantification of cFOS was conducted as previously described 37
